Clinical Trial Update: Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II study of Intraperitoneal NanoPac in ovarian cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Carcinoma

Drugs mentioned

• NanoPac (paclitaxel nanoparticle formulation)

Snippet

Sponsor: NanOlogy, LLC | Conditions: Ovarian Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-04-27